PGIM標普500緩衝12主動型ETF-3月 MRCP 深 滬
交易中 11-11 11:00:09 美东时间
35.325
+0.161
+0.46%
華盛通- 最 高35.325
- 今 開35.30
- 成交量 2008股
- 最 低 35.30
- 昨 收 35.1637
- 總市值 3532.50万
- 52周最高 35.63
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 31.05
- 委 比 0.00%
- 總股本 100.00万
- 歷史最高 35.63
- 量 比 7.60
- 振 幅 0.07%
- 歷史最低 24.7042
- 每 手 1
- 風險率 1.41%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Aligos Therapeutics Presents Positive Data at The Liver Meeting® 2026
Aligos Therapeutics announced positive data from five presentations at the AASLD Liver Meeting 2026, highlighting advancements in chronic HBV treatment. Pevifoscorvir sodium showed potential in reducing pro-inflammatory cytokines and inhibiting viral DNA forms linked to disease progression. ALG-170675, a next-generation antisense oligonucleotide, demonstrated superior HBsAg knockdown in preclinical studies. Additional research showcased innovativ...
11-05 21:05
Adial Pharmaceuticals Announces Name Change to Azora Therapeutics and New Executive Team, Focused on Advancing AT177, an Oral, Colon-Targeted AhR Agonist for Ulcerative Colitis
Azora Therapeutics, Inc. has renamed from Adial Pharmaceuticals and its common stock will trade on Nasdaq under "AZR" starting Oct. 29, 2026. Shareholders approved the conversion of Series A preferred stock to common stock. The company, focused on treating inflammatory diseases, has a new executive team led by Matt Davidson, Ph.D., and Julie Saiki, Ph.D., with deep experience in drug development. Azora's lead asset, AT177, an oral, colon-targeted...
10-28 20:02
